Clinical Trial Update: A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 clinical study evaluating YTS109 cells in relapsed/refractory systemic lupus erythematosus, including lupus nephritis and immune thrombocytopenia, is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• YTS109 cell (YTS109)

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Lupus Nephritis (LN), Immune Thrombocytopenia (ITP) | Phase 1 | Status: RECRUITING